Drug Profile
Pneumococcal vaccine conjugate 13-valent - Sinovac Biotech
Alternative Names: CRM197,TT; PCV 13i; Pneumococcal 13-valent vaccine - Sinovac BiotechLatest Information Update: 01 Jan 2024
Price :
$50
*
At a glance
- Originator Sinovac Biotech
- Class Pneumococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Pneumococcal infections
Most Recent Events
- 27 Dec 2023 Sinovac Research and Development in collaboration with CanSino Biologics plants to initiate a phase I trial for Pneumococcal infections (Prevention, In infants and In children) in China in January 2024 (IM) (NCT06183216)
- 03 Jan 2023 Sinovac initiates a phase I trial in Pneumococcal Infections (Prevention, In infants, In children, In adolescents, In adults) in China (IM) (NCT05092386)
- 30 Dec 2022 Phase-I development is ongoing in Bacterial infections, Pneumococcal infections and Streptococcal infections (Prevention) in China (IM) (NCT04100772)